Oragenics (NYSE:OGEN) Now Covered by StockNews.com

by · The Cerbat Gem

StockNews.com started coverage on shares of Oragenics (NYSE:OGEN – Free Report) in a research report sent to investors on Tuesday morning. The brokerage issued a sell rating on the stock.

Oragenics Stock Performance

Shares of NYSE OGEN opened at $0.33 on Tuesday. The company’s 50 day moving average price is $0.34 and its 200-day moving average price is $0.65. Oragenics has a 52-week low of $0.25 and a 52-week high of $6.42. The company has a market capitalization of $4.07 million, a P/E ratio of -0.05 and a beta of 0.40.

Oragenics Company Profile

(Get Free Report)

Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.

Featured Stories